Document Classification

Section Type: METHODS

Text: In the main 26-week randomized, open-label study (n = 658), liraglutide, 1. 2 or 1. 8 mg, injected with a pen, led to greater HbA1c reduction than oral sitagliptin, 100 mg once daily, both added to metformin = 1500 mg daily : mean HbA1c reduction was 1. 5, 1. 2 and 0. 9 % (7, 10 and 14 mmol/mol) for liraglutide 1. 8 mg, 1. 2 mg and sitagliptin, respectively (P < 0. 0001 for both liraglutide doses vs. sitagliptin) and liraglutide patients lost more weight (3 vs. 1 kg ; P < 0. 0001).